凯莱英医药集团（天津）股份有限公司（06821）10月9日公告称，其董事会将于2026年10月22日（星期四）召开会议，主要议程包括审议并批准公司及其附属公司截至2026年9月30日止九个月的第三季度业绩及相关公告，并处理其他事项（如有）。\n\n公告显示，董事会由董事长兼执行董事Hao Hong博士，执行董事杨蕊女士、张达先生及洪亮先生，非执行董事Ye Song博士及张婷女士，以及独立非执行董事孙雪娇博士、侯欣一博士和谢维愷先生组成。\n\n凯莱英表示，董事会将于会后及时发布相关业绩信息，供投资者参考。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.